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C5b-9 regulates peritubular myofibroblast accumulation in ex-
perimental focal segmental glomerulosclerosis.
Background. In human focal segmental glomerulosclerosis
(FSGS), the tubulointerstitial deposition of the complement
(C5b-9) membrane attack complex is correlated with intersti-
tial myofibroblast accumulation and proteinuria. Here, we hy-
pothesized that C5b-9 formation regulates renal myofibroblast
accumulation in Adriamycin nephropathy.
Methods. Adriamycin nephropathy was induced in comple-
ment C6-sufficient (C6+) and C6-deficient (C6−) piebold viral
glaxo (PVG) rats. Groups of animals (N = 7 to 8 each) were
examined on days 21 and 42. A group of C6+ animals, injected
with vehicle, served as the control group.
Results. C6+ and C6− rats with Adriamycin nephropathy
had equivalent proteinuria. C5b-9 deposition was increased and
present on the apical surface of proximal tubular epithelial
cells (day 21 and 42) and peritubular region (day 42 only) in
C6+ rats with Adriamycin nephropathy, and absent in C6−
rats. Peritubular myofibroblast accumulation increased in a
time-dependent manner in C6+ proteinuric rats (control 1.2 ±
0.4; Adriamycin nephropathy day 21 11.0 ± 0.7; Adriamycin
nephropathy day 42 19.8 ± 1.7 cells per high power field). In
C6− rats this increase was blunted by 87% and 56% on days
21 and 42, respectively (P < 0.01), and was associated with
reduced interstitial extracellular matrix (ECM) deposition.
Tubulointerstitial injury, tubular vimentin and interstitial mono-
cyte accumulation were also reduced in C6− rats with Adri-
amycin nephropathy on day 21, but not at day 42. In contrast,
the increase in periglomerular myofibroblast accumulation and
glomerulosclerosis in Adriamycin nephropathy were not al-
tered by C6 deficiency.
Conclusion. These data suggest that glomerular ultrafiltra-
tion of complement components and the intratubular formation
of C5b-9 is a specific promotor of peritubular myofibroblast ac-
cumulation in FSGS.
Primary focal segmental glomerulosclerosis (FSGS)
is a noninflammatory glomerulonephritis, characterized
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by persistent nephrotic syndrome, nonselective protein-
uria, microscopic hematuria, hypertension, and renal im-
pairment [1]. Irreversible injury to podocytes underlies
the glomerular permselectivity loss, and in humans, the
cause/s may include a circulating podocyte toxic per-
meability factor, congenital and acquired mutations in
podocytes proteins, and/or viral infection [1]. Nephrotic-
range proteinuria, chronic tubulointerstitial damage, and
corticosteroid resistance are predictors of a poor renal
prognosis in FSGS [1–3]. In such patients, currently avail-
able treatments are disappointing, and the clinical course
is characterized by progressive deterioration to end-stage
kidney failure in up to 50% of patients over a 10-year
period [1].
Considerable evidence is accumulating that the
glomerular ultrafiltration of serum-derived complement
components and formation of the terminal membrane
attack complex (C5b-9) in the tubular lumen is an impor-
tant mechanism of tubulointerstitial damage in nephrotic
glomerular diseases [4–9]. Clinical evidence to support
this hypothesis in FSGS include (1) compared to other
glomerular diseases, patients with FSGS have one of the
highest rates of urinary C5b-9 excretion (15-fold higher
than controls in one study), which is second only to di-
abetic nephropathy (increased more than 30-fold) [10,
11]; and (2) the tubulointerstitial deposition of C5b-9 is
increased in patients with FSGS, particularly in those that
do not respond to treatment with corticosteroids [12, 13].
Renal myofibroblast accumulation is also increased in
patients with FSGS [13, 14]. Myofibroblasts are activated
smooth muscle–like fibroblasts, phenotypically charac-
terized by the filamentary expression of alpha-smooth
muscle actin (a-SMA), vimentin, and desmin [15]. In
tubulointerstitial damage, myofibroblasts could act as
sentinel inflammatory cells [16], contribute extracellular
matrix (ECM) deposition [15], and their fibrocontrac-
tile properties might theoretically lead to strangulation
of tubules resulting in atubular glomeruli [17, 18]. Renal
myofibroblast accumulation is also a predictor of progres-
sion in a variety of human glomerular diseases [19, 20].
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These data therefore potentially implicate the myofibrob-
last as a significant cellular player in tubulointerstitial
damage associated with FSGS. However, the mechanisms
of myofibroblast accumulation in FSGS are poorly un-
derstood. It has been suggested that components of pro-
teinuric urine could promote peritubular myofibroblast
accumulation [20]. Interestingly, in patients with FSGS,
the tubulointerstitial expression of C5b-9 is correlated
with peritubular, but not periglomerular, a-SMA, accu-
mulation [13].
Adriamycin nephropathy is a nonimmune mediated
nephrotic rat model of FSGS [21]. The pathologic changes
include early and prominent tubulointerstitial damage;
podocyte foot effacement and detachment; and glomeru-
lar changes, which evolve from minimal change lesions
into FSGS [21, 22]. Rodent Adriamycin nephropathy,
similar to human FSGS, is resistant to corticosteroids [23]
and shows variable renoprotection to angiotensin block-
ade [24]. In contrast to human FSGS, however, glomeru-
lar injury in rodent Adriamycin nephropathy is initiated
by irreversible toxic injury to the glomerular capillary
wall and podocytes by doxorubicin [21]. The aim of the
present study was to examine the hypothesis that, in
Adriamycin nephropathy, the increased glomerular fil-
tration of complement components and formation of the
membrane attack complex regulates renal myofibrob-
last accumulation. To test this hypothesis, Adriamycin
nephropathy was induced in complement sufficient
(C6+) and complement deficient (C6−) piebold-viral
glaxo (PVG) rats, which are unable to form C5b-9 [25].
METHODS
Experimental animals
Forty two age and litter-matched adult male PVG rats
(approximately 10 to 12 weeks in age; initial body weight
280 ± 1.5 g, mean ± SE) with (N = 26) or without C6
(N = 16) deficiency were obtained from the breeding
colony at the University of Washington, Seattle, Washing-
ton. The original source for the breeding pairs with nor-
mal complement activity was Harlan-Sprague-Dawley
(Cambridge, UK), and complement deficient was Bantin
and Kingman Universal (Edmonds, Washington). Before
the studies were commenced the complement status of
each PVG rat was verified by measuring the hemolytic
activity of serum by a standard CH50 assay as previously
described [26]. All rats were housed in groups of two to
three per cage in a temperature and light-controlled en-
vironment in accredited animal facility, with free access
to food and water. The studies were performed in accor-
dance with National Institutes of Health Guide for the
Care and Use of Laboratory animals. The Ethics Com-
mittee of the University of Washington, Seattle, approved
protocols.
Induction of Adriamycin nephropathy
Adriamycin nephropathy was induced in an identical
manner in C6+ (N = 16) and C6− (N = 16) male rat lit-
termates by a single intravenous injection of doxorubicin
hydrochloride (6.0 mg/kg) under anesthesia (single in-
traperitoneal injection of ketamine:xylazine 90:10 mg/kg)
on day 0 [22]. A separate group of C6+ animals (N = 10)
received a single injection of saline (vehicle) instead of
doxorubicin. Groups of animals were sacrificed on day
21 and 42 (N = 8 each, C6+ and C6−, per Adriamycin
nephropathy group and time point; N = 5 each, per con-
trol group and time point). One C6-sufficient animal with
Adriamycin nephropathy (from the day 42 group) devel-
oped tense abdominal swelling due to ascites on day 34.
Euthanasia was performed on day 35 due to respiratory
distress. This rat was excluded from all subsequent anal-
yses. The dose of Adriamycin chosen for this study was
lower than previous studies (7.5 mg/kg [22]), because pre-
liminary experiments showed that this dose caused more
severe systemic Adriamycin toxicity (weight loss) in both
C6+ and C6− PVG rats. The time points (days 21 and
42) were chosen according to previous studies using this
model [22]. One day prior to tissue collection, animals
were placed in metabolic cages for 17 hours to determine
urine protein and creatinine excretion. At the time of sac-
rifice, animals were anesthetized with ketamine:xylazine,
a midline laparotomy was performed, blood was col-
lected from the inferior vena cava, and both kidneys were
removed.
Renal function
Renal function and assessment of nephrotic syndrome
was assessed by measuring urinary protein excretion,
serum creatinine, urea, albumin, and cholesterol. Serum
urea, creatinine, albumin, and cholesterol were measured
by an autoanalyser (Hitachi B747) (PathCentre, QEII
Medical Center, Nedlands, WA, Australia). Urinary pro-
tein excretion was measured by the sulfosalicylic acid
method.
Renal histology and immunohistochemistry
Coronal sections of the kidney were immersion-fixed
in methyl Carnoy’s solution or 10% neutral-buffered for-
malin and embedded in paraffin. Light microscopy was
performed on 4 lm sections of tissue stained with either
periodic acid-Schiff (PAS) reagent (counterstained with
hematoxylin) or Masson’s trichrome.
Immunoperoxidase staining was performed as previ-
ously described [7, 8] using the following antibodies:
a murine monoclonal IgG2 antibody against a-SMA,
a cytoskeletal marker of myofibroblastic differentiation
(Sigma-Aldrich Chemical Co., St. Louis, MO, USA);
a rabbit polyclonal antibody against rat fibronectin
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(Chemicon, Temecula, CA, USA); a murine monoclonal
IgG antibody V9 against vimentin (Dako, Carpinteria,
CA, USA); and a murine monoclonal IgG1 antibody
against ED-1, a cytoplasmic antigen present in mono-
cytes, macrophages, and dendritic cells (Bioproducts
for Science, Inc., Indianapolis, IN, USA). Horseradish
peroxidase-conjugated avidin D (Vector Laboratories,
Burlingame, CA, USA) was used after all biotiny-
lated secondary antibodies at room temperature for
20 minutes. The chromogen was developed with 3,3-
diaminobenzidine tetrahydrochloride (DAB). Sections
were counterstained with methyl green. As a negative
control, the primary antibody was omitted or substituted
with preimmune rabbit, mouse or goat serum, corre-
sponding to the species of the primary antibody.
Tissue for immunofluorescence was embedded in 22-
oxacalcitriol (OCT) compound (Lab-Tek Products, Miles
Laboratories, Naperville, IL, USA) and snap-frozen in
liquid nitrogen. Rat C3 was detected with fluorescein
isothiocyanate (FITC)-conjugated goat antirat C3 (ICN
Pharmaceuticals, Irvine, CA, USA). The presence of rat
C5b-9 was determined using biotinylated antirat C5b-9
monoclonal antibody 2A1 followed by FITC-streptavidin
[8, 9, 22].
Quantitation of renal histology and
immunohistochemistry
For quantitation of cells (a-SMA, ED-1), the number
of nuclei with DAB-positive cytoplasmic staining was
determined. In the cortical interstitial space, the num-
ber of DAB-positive cells was counted in 20 nonover-
lapping random fields (at a magnification of ×200),
using a 0.5 mm2 graticule fitted in the eyepiece of a mi-
croscope (BX51) (Olympus Australia, Welshpool, WA,
Australia). The mean number per animal was calculated
and expressed per mm2 area. Similarily, in the glomeru-
lus, the number of periglomerular a-SMA–positive cells
was counted in at least 20 glomerular cross-sections per
animal (magnification ×400).
For quantitation of tubular vimentin, the number
of positive tubular cross-sections was counted in 20
nonoverlapping random fields (magnification of ×200
using a 0.5 mm2 graticule). In order for tubules to be
counted positive (and assigned a value of 1.0), at least
one tubular epithelial cell in the tubular cross-section had
to be DAB-positive. The mean number per animal was
calculated.
Interstitial fibronectin was assessed by computer-
assisted image analysis. For each animal, images were
taken of 20 nonoverlapping random fields of the cor-
tical interstitium not containing glomeruli (magnifica-
tion of ×400) using a digital camera (Olympus DP11,
2MP, Olympus Australia, Welshpool, WA, Australia).
The JPEG images were downloaded to a desktop com-
puter, and the percent area occupied by interstitial fi-
bronectin was calculated using image-analysis software
(Optimas 6.51, Media Cybernetics, Silver Spring, MD,
USA).
Tubulointerstitial injury (defined as tubular atrophy,
dilatation, thickening of the basement membrane) and
interstitial fibrosis (blue stain in Trichome-stained sec-
tions) by semiquantitative analysis [8, 9]. Thirty cortical
fields from each animal were examined at ×200 magnifi-
cation using a graticule (0.5 mm2) and graded according
to a scale of 0 to 4: 0, no tubulointerstitial injury or absent
interstitial collagen deposition; 1, <25% of the tubuloint-
erstitium injured or minimal deposition of interstitial col-
lagen (<25%); 2, 25% to 50% of the tubulointerstitium
injured or mild deposition of interstitial collagen (25%
to 50%); 3, 51% to 75% of the tubulointerstitium injured
or mild deposition of interstitial collagen (51% to 75%);
and 4, 76% to 100% of the tubulointerstitium injured or
diffuse deposition of interstitial collagen (>75%).
Statistical analysis
Data are expressed as mean ± SE. Comparisons be-
tween experimental groups were performed using the in-
dependent t test for parametric data, and Kruskal-Wallis
test for nonparametric data. Tests to determine the distri-
bution of data and all other calculations were performed
using statistical software (JMP version 4.04) (SAS Insti-
tute, Carey, NC, USA). A P < 0.05 value was defined as
being statistically significant.
RESULTS
Tubulointerstitial C5b-9 is increased in Adriamycin
nephropathy
In control animals, C5b-9 immunoreactivity was rarely
present, and localized as focal peritubular deposits
(Fig. 1A and D). In C6+ rats with Adriamycin nephropa-
thy, C5b-9 staining was increased. On day 21, C5b-9 was
predominantly present in the lumen and apical surfaces of
proximal tubular epithelial cells, similar to that observed
in rats with puromycin aminonucleoside nephrosis (PAN)
(Fig. 1B) [7]. In contrast, by day 42, C5b-9 staining was
also increased in the peritubular region of the tubuloin-
terstitium in nephrotic C6+ rats (Fig. 1E). Glomerular
C5b-9 staining was absent in C6+ rats with Adriamycin
nephropathy. Renal C5b-9 staining was completely ab-
sent in C6− animals (Fig. 1C and E).
C3 staining was present in a peritubular distribution
in control animals and this was increased in rats with
Adriamycin nephropathy (Fig. 1G). In addition, in Adri-
amycin nephropathy C3 was also detected in the lumen,
apical surfaces and cytoplasm of tubular epithelial cells in
C6+ rats with Adriamycin nephropathy. Tubulointersti-
tial C3 staining was similar in magnitude and distribution
in both the C6− or C6+ groups at day 21 (Fig. 1G and
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Control C6+/AN C6−/AN
Fig. 1. Immunofluorescence microscopy of C5b-9 and C3 in the renal cortex. (A to C) Day 21 (C5b-9). (D to F) Day 42 (C5b-9). (G to I) Day
21 (C3). (A, D, and G) Saline-injected control C6+ animals. (B, E, and H) C6+ animals with Adriamycin nephropathy (AN). (C, F, and I) C6−
animals with Adriamycin nephropathy (magnification ×400 for C5b-9; ×200 for C3).
H) and 42. Glomerular C3 staining was not detected in
either group with Adriamycin nephropathy.
Body weight and kidney weight are similar in C6−
and C6+ rats
Rats with Adriamycin nephropathy gained less body
weight (Table 1), but no differences between the C6+
and C6− Adriamycin nephropathy groups, at any time
point, were observed. Kidney weight increased in groups
with Adriamycin nephropathy compared to the control
group, but was not altered by C6-deficiency.
Proteinuria, renal function, and markers of nephrotic
syndrome are similar in C6− and C6+ rats
In Adriamycin nephropathy, proteinuria increased and
was 20-fold greater than that of control (vehicle-injected)
animals (Fig. 2). The proteinuria peaked on day 21 and
remained elevated on day 42 (Fig. 2). Levels of protein-
uria were the same in both C6+ and C6− groups with
Adriamycin nephropathy on both day 21 and day 42.
Renal function, as assessed by elevation in the serum
urea and creatinine, deteriorated in rats with Adriamycin
nephropathy (Table 1). The absence of C6 did not alter
the decline in renal function or development of biochem-
ical markers of nephrotic syndrome (hypoalbuminemia,
hypercholesterolemia) at any time point (Table 1).
Peritubular myofibroblast accumulation is attenuated in
C6− rats on days 21 and 42
In control animals, a-SMA was strongly expressed in
vascular smooth muscle cells of arteries, arterioles and
smaller capillaries (Fig. 3A and D). In C6+ rats with
Adriamycin nephropathy, the number of peritubular cells
positive for a-SMA increased in a time-dependent man-
ner (Figs. 3 and 4). Typically, the vast majority of these
cells were elongated and located in a peritubular dis-
tribution, with their cellular processes almost surround-
ing the cross-section of a tubule. Round interstitial cells
without elongated processes were also present, but much
less common. In C6− rats with Adriamycin nephropathy,
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Table 1. Body weight (BW), kidney weight (KW), and renal function in the experimental groups
Final KW/BW PUr PCr PChol
Group Initial BW BW g KW g g/100g mmol/L lmol/L Palb g/dL mmol/L
Day 21
Control 282 ± 1 290 ± 2 0.87 ± 0.01 0.30 ± 0.003 7.3 ± 0.2 37.8 ± 1.5 36.1 ± 0.7 2.2 ± 0.1
C6+ 281 ± 2 260 ± 3a 1.12 ± 0.04a 0.43 ± 0.02a 11.9 ± 1.0a 70.9 ± 6.8a 14.4 ± 0.2a 13.7 ± 0.5a
C6− 280 ± 2 271 ± 2a 1.06 ± 0.03a 0.39 ± 0.01a 11.8 ± 0.6a 76.3 ± 9.7a 15.0 ± 0.5a 14.9 ± 0.7a
Day 42
Control 284 ± 2 310 ± 3 0.87 ± 0.004 0.28 ± 0.003 6.9 ± 0.3 39 ± 2.1 35.7 ± 1.1 2.0 ± 0.1
C6+ 281 ± 3 243 ± 6a,b 1.05 ± 0.05a,b 0.43 ± 0.02a,b 17.9 ± 1.9a,b 112.2 ± 5.6a,b 16.7 ± 0.4a 16.1 ± 1.4a
C6− 282 ± 2 237 ± 5a,b 1.07 ± 0.04a,b 0.45 ± 0.01a,b 20.9 ± 1.2a,b 97.8 ± 8.5a,b 15.4 ± 0.3a 17.3 ± 0.8a
Abbreviations are: SUr, plasma urea; PCr, plasma creatinine; Palb, plasma albumin; Pchol, plasma cholesterol. Data expressed as mean ± SE.
aP < 0.05 compared to control group.
bP < 0.05 compared to day 21 group.
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Fig. 2. Proteinuria in the experimental groups. Data expressed as mean
± SE. ∗P < 0.01 compared to control.
peritubular a-SMA accumulation was reduced (Figs. 3
and 4). This was most dramatic on day 21 when almost
no a-SMA–positive cells were present in the interstitium,
and partial on day 42.
Periglomerular myofibroblast accumulation is not altered
in C6− rats at any time point
In control animals, there were no a-SMA–positive
cells around glomeruli (Fig. 5A and D). In Adriamycin
nephropathy, there was a dramatic increase in a-SMA–
positive cells around glomeruli (Figs. 4 and 5). The inten-
sity of cytosolic staining and number of cells was more
prominent on day 42. However, there was no difference
in number of periglomerular a-SMA–positive cells be-
tween the C6+ and C6− groups at either day 21 or 42
(Figs. 4 and 5).
Interstitial ECM deposition is attenuated in C6− rats on
days 21 and 42
We next assessed whether the changes in myofi-
broblast accumulation were associated with alterations
extracellular matrix in the interstitium [27, 28]. By
Trichome staining, interstitial fibrosis increased in a time-
dependant manner in Adriamycin nephropathy (Fig. 6).
In C6-deficient animals, interstitial fibrosis was reduced
on day 21 (P < 0.01) and day 42 compared to C6-sufficient
(P < 0.001) (Fig. 6). Similarly, interstitial fibronectin de-
position was also reduced in C6− rats with Adriamycin
nephropathy, both on day 21 and day 42 (Fig. 6).
Markers of tubular injury and dedifferentiation are
reduced in C6− rats on day 21 only
We next asked the question as to whether the decrease
in myofibroblast accumulation in C6-deficient rats was
due to a reduction in tubular epithelial cell injury [28, 29].
By semiquantitative analysis, tubulointerstitial injury was
attenuated in C6− rats with Adriamycin nephropathy on
day 21 (P < 0.05) but not at day 42 (Figs. 7 and 8A).
Similarly, the number of tubules positive for vimentin was
reduced at day 21 (P < 0.01) but not at day 42 (Fig. 8B).
Therefore, attenuation of tubular injury did not explain
the sustained reduction in myofibroblast accumulation in
C6-deficient rats on day 42.
Interstitial monocyte accumulation is reduced in C6−
rats on day 21 only
Because interstitial myofibroblast accumulation could
be mediated by paracrine effects of macrophage [30], we
examined whether ED-1 cell accumulation altered. In-
terstitial monocyte accumulation was increased in Adri-
amycin nephropathy (P < 0.01). Interstitial ED-1 accu-
mulation was partly reduced on day 21 in C6− rats with
Adriamycin nephropathy (P < 0.05), but this reduction
was not sustained to day 42 (Fig. 8C).
Glomerulosclerosis and glomerular monocyte
accumulation are not altered in C6− rats
There was a mild increase in glomerulosclerosis in rats
with Adriamycin nephropathy. However, the absence of
C6 did not alter the progression of glomerulosclerosis
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Fig. 3. Peritubular myofibroblast accumulation as determined by a-smooth muscle actin (a-SMA) immunohistochemistry. (A and D) Saline-injected
control animals. (B and E) C6+ animals with Adriamycin nephropathy (AN). (C and F) C6− animals with Adriamycin nephropathy (magnification
×200).
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Fig. 4. Quantitation of peritubular (A) and periglomerular (B) a-
smooth muscle actin (a-SMA)–positive cells. In the experimental
groups on day 21 (d21) and day 42 (d42). Data expressed as mean + SE.
∗P < 0.01 compared to control; #P < 0.01 compared to C6+/Adriamycin
nephropathy (AN). Grey bars are C6+, white bars are C6−.
(Fig. 9A to C) or glomerular ED-1 cell accumulation
(Fig. 9D to F).
DISCUSSION
The results of this paper show that the tubulointer-
stitial assembly of complement membrane attack com-
plex, from serum-derived components in proteinuric
urine, leads to the accumulation of myofibroblasts in
the peritubular space, in Adriamycin nephropathy. The
main findings were (1) C5b-9 formation was increased in
the lumen and peritubular regions in kidney from rats
with Adriamycin nephropathy; (2) the absence of tubu-
lointerstitial C5b-9 formation in C6-deficient rats with
Adriamycin nephropathy dramatically reduced the ac-
cumulation of a-SMA–positive peritubular cells; (3) re-
nal interstitial fibrosis and fibronectin deposition (an
ECM protein product of myofibroblasts) were reduced
in C6-deficient rats with Adriamycin nephropathy; and
(4) remarkably, the effects of C5b-9 on myofibroblasts
were highly compartment-specific, because periglomeru-
lar accumulation of myofibroblast was not altered by C6-
deficiency. Another important finding of this study was
that tubular injury and activation, and interstitial mono-
cyte infiltration were reduced in early, but not in the late
stages of Adriamycin nephropathy.
Peritubular and periglomerular myofibroblast accumu-
lation is increased in a variety of human and experimental
models of chronic renal disease, and predicts a poor prog-
nosis [19, 20]. In humans with primary FSGS, peritubular
myofibroblast accumulation is also increased [13, 14] and
correlated with the tubulointerstitial formation of C5b-9
[13]. In the remnant kidney model, protein overload of
proximal tubular epithelial cells (in particular IgG) was
associated with peritubular a-SMA accumulation [20].
Furthermore, reduction of proteinuria (and IgG accumu-
lation in tubular cells) with an angiontensin-converting
enzyme (ACE) inhibitor suppressed peritubular a-SMA
accumulation [20]. The current study provides the first in
vivo evidence directly demonstrating that C5b-9 is one
of the components in proteinuric urine that is important
in regulating peritubular myofibroblast accumulation in
chronic proteinuric renal disease.
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Fig. 5. Periglomerular myofibroblast accumulation. (A and D) Saline-injected control animals. (B and E) C6+ animals with Adriamycin nephropa-
thy (AN). (C and F) C6− animals with Adriamycin nephropathy (magnification ×400).
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Fig. 6. (A) Interstitial fibrosis in Trichrome-stained sections (×200) and interstitial fibronectin deposition (×400) in the renal cortex on day
42. (B) Quantitative data for interstitial fibrosis and interstitial fibronectin deposition. Data expressed as mean + SE, #P < 0.01 compared to
C6+/Adriamycin nephropathy (AN). Grey bars are C6+, white bars are C6−.
The origin of myofibroblasts in Adriamycin nephropa-
thy and human FSGS remains uncertain, and could
include differentiation from fibrogenitor stem cells or cir-
culating precursor cells [15]; proliferation and increased
survival of myofibroblasts [31]; and/or transdifferentia-
tion from pericytes or proximal tubular epithelial cells
[20, 32]. In Adriamycin nephropathy, at least four mech-
anisms could be involved in C5b-9–induced peritubu-
lar myofibroblast accumulation: (1) differentiation of
local fibrogenitor cells due to the paracrine effects of
fibrogenic growth factors [interleukin (IL)-1, transform-
ing growth factor-a (TNF-a), platelet-derived growth
factor (PDGF), fibroblast growth factor (FGF), and
transforming growth factor-b1 (TGF-b1)] released from
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Control C6+/AN C6-/AN
Day 21
Day 42
A B C
D E F
Fig. 7. Tubulointerstitial injury in periodic acid-Schiff (PAS)-stained sections. (A and D) Saline-injected control animals. (B and E) C6+ rats with
Adriamycin nephropathy (AN). (C and F) C6− rats with Adriamycin nephropathy (magnification ×200).
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Fig. 8. Quantitation of cortical tubulointerstitial injury, vimentin-
positive tubules, and interstitial endothelin-1 (ED-1)+ cell accumu-
lation in the experimental groups. Data expressed as mean + SE. #P <
0.01 compared to C6+/Adriamycin nephropathy (AN). Grey bars are
C6+, white bars are C6−.
tubular epithelial cells exposed to C5b-9 [29, 33]. How-
ever, in coculture cell culture studies from our labora-
tory, the proliferation of normal human dermal fibrob-
lasts was reduced when exposed to supernatants from
human HK-2 cells (a proximal tubular epithelial cell line)
stimulated with complement-sufficient serum compared
to complement-deficient serum [abstract P125; Rangan
GK, et al, Nephrology 7(Suppl):A74, 2002]. (1) These
data suggest that complement does not increase the re-
lease of fibroblast mitogens by tubular cells; (2) differen-
tiation of local fibrogenitor cells is due to the paracrine
effects of macrophages, attracted because of chemokines
released by C5b-9–activated tubular cells [15, 33]. How-
ever, in our study, monocyte accumulation and tubular
epithelial cell injury was not altered on day 42, suggest-
ing that this is only a partial explanation; (3) prolifer-
ation and activation of fibroblasts follows direct contact
with C5b-9 in the interstitial space [34]. In our study, how-
ever, C5b-9 was only detected in the peritubular region on
day 42, whereas myofibroblast accumulation was reduced
prior to this time point; and (4) mesenchymal transition
of tubular epithelial or endothelial cells into myofibrob-
lasts is stimulated by C5b-9 [20, 32]. We postulate that all
of these mechanisms probably have a role, to varying de-
grees, in FSGS and other nephrotic glomerular disorders,
depending on the stage of the disease.
The current study extends previous data about the im-
portance of C5b-9 as a mediator of tubular injury and
interstitial inflammation [4–9]. In particular, recently
Turnberg et al reported that tubulointerstitial damage
was exacerbated in mice with Adriamycin nephropathy,
that were deficient in CD59 (a complement regulatory
protein that inhibits C5b-9) [abstract F-PO463; Turnberg
et al, J Am Soc Nephrol 14:163A, 2003]. In previous
studies we demonstrated that the absence of C6 atten-
uated tubulointerstitial damage in rats with PAN and
the remnant kidney model [7, 8]. The present study fur-
ther extends these findings in an irreversible and non-
ablative model of FSGS. However, an extremely impor-
tant finding of the current study (which contrasts with
our data in PAN and remnant kidney studies) was that
tubular injury (as determined by semiquantitative scor-
ing system and vimentin expression) was almost com-
pletely attenuated during the early time point of Adri-
amycin nephropathy (day 21), but not at the later time
point (day 42). Similarly, interstitial monocyte accumula-
tion was suppressed by nearly 50% (but still significantly
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Fig. 9. Glomerulosclerosis in periodic acid-Schiff (PAS)-stained sections (A to C) and glomerular ED-1 accumulation (D to F) on day 42. AN is
Adriamycin nephropathy (magnification ×200).
elevated compared to control animals) on day 21, but not
on day 42. These pathologic findings, along with the per-
sistence of proteinuria, could explain why C6-deficiency
also did not alter the decline in renal function in Adri-
amycin nephropathy at any time point [35]. Moreover, the
current data suggests that, at least in Adriamycin
nephropathy, other mediators are also involved in causing
tubulointerstitial injury. With regard to other components
of the complement cascade, for example, the deficiency
of C6 does not prevent activation such as C5a [36]. In that
respect, Welch et al [37] reported that C5a is an important
regulator of interstitial inflammatory cell accumulation in
mice with chronic proteinuric renal disease.
An interesting observation of the current study was
the presence of C5b-9 in the lumen of tubular epithelial
cells (at day 21) and also peritubular regions (at day 42) in
Adriamycin nephropathy. In previous studies of the PAN
and remnant kidney models [7, 8], C5b-9 was restricted
only to the lumen of tubular epithelial cells. The luminal
formation of C5b-9 from filtration of complement com-
ponents is thought to be due to at least three mechanisms:
(1) C3-convertase activity of the proximal tubular epithe-
lial cell brush border [38]; (2) amidation of C3 by ammo-
nia [4]; and (3) absence of CD59 on the tubular lumen
[39]. However, peritubular C5b-9 formation is not un-
expected, and, in fact, consistent with pathologic studies
of human renal diseases (including FSGS) [40, 41]. C5b-
9 formation under these circumstances could be due to
extravasation of complement components in an inflamed
tissue microenvironment catalyzed by the C3-convertase
activity of damaged parenchymal cells [42]. Another pos-
sibility is that peritubular C5b-9 could also arise from mis-
directed glomerular ultrafiltrate as suggested by Kriz [17],
although this might be a relative late mechanism in Adri-
amycin nephropathy (occurring at 16 weeks) [18]. At least
theoretically, peritubular C5b-9 could have direct sublytic
effects on interstitial cells and thereby contribute to tubu-
lointerstitial damage [34, 43]. However, in separate stud-
ies from our laboratory, tubulointerstitial damage in rats
with ureteric obstruction and cyclosporin nephropathy
(in which tubulointerstitial, but not luminal C5b-9, depo-
sition is present due to the absence of proteinuria) was
not altered by C6-deficiency [abstract P126, Rangan GK,
et al, Nephrology, 7(Suppl):A74, 2002]. These data sug-
gest that peritubular C5b-9 is not essential for tubuloint-
erstitial damage, or that other additional mechanisms are
involved in renal diseases characterized by proteinuria.
In a previous study in Adriamycin nephropathy, tubu-
lointerstitial damage was not altered in rats with a con-
genital deficiency of albumin [44]. It is possible that the
persistence of other components of proteinuric urine [45],
or lipid moieties bound to plasma proteins in the anal-
buminemic rats [46], ensured that tubulointerstitial le-
sions developed in these animals. Indeed, the data from
the present study directly supports that complement (and
C5b-9) is one of the principal noxious filtered proteins.
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The relative significance of other noxious proteins, such
as transferrin and immunoglobulins, requires further in-
vestigation.
Although the pathologic lesions in Adriamycin
nephropathy resemble human FSGS, the limitations of
this model are that the etiology of glomerular injury is
different to human disease, and the extent to which dox-
orubicin per se contributes to tubulointerstitial lesions in
Adriamycin nephropathy is unknown [21]. In the current
study both the C6-sufficient and deficient groups were
matched by body weight and age, and all animals received
an identical dose of Adriamycin. Moreover, glomerular
injury, proteinuria and markers of nephrotic syndrome
(hyperlipidemia and hypoalbuminemia) were similar the
C6+ and C6− groups. Therefore, differences in dose of
Adriamycin, degree of glomerular injury or systemic ef-
fects of nephrotic syndrome could not explain the strik-
ing reduction in peritubular myofibroblast accumulation
in C6-deficient group.
CONCLUSION
The present study provides further evidence for com-
plement and C5b-9 as a pathogen for tubulointerstitial
damage associated with nephrotic glomerular dis-
eases, such as FSGS. This together with other studies
[4–13] gives substantial preclinical support for the test-
ing and development of an inhibitor of C5b-9 forma-
tion in chronic proteinuric renal disease, preferably one
that is orally active, cost-effective and renal-specific.
Clearly, such a therapy could “complement” existing
renoprotective agents, and hopefully make treatment of
steroid-resistant FSGS far more gratifying for the clinical
nephrologist in the future.
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